Hospital
Willamette Valley Medical Center LLC
Willamette Valley Medical Center LLC was paid $17.29M by Medicaid between Jan 2018 and Nov 2024, across 97 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoWILLAMETTE VALLEY MEDICAL CENTER LLC
MCMINNVILLE, OR 97128
MCMINNVILLE, OR 97128
33aNPI1346269982assigned 07/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.29M
24GClaims256,422
24DCodes billed97
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oregon
Rank by total paid#8 of 17
Median peer was paid$13.35M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,922 | $2.12M | |
| 2019 | 40,418 | $2.34M | |
| 2020 | 31,632 | $1.90M | |
| 2021 | 36,637 | $2.23M | |
| 2022 | 40,581 | $2.59M | |
| 2023 | 37,321 | $3.20M | |
| 2024incomplete | 29,911 | $2.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 24,814 | 21,349 | $5.27M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 33,876 | 30,323 | $5.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 9,911 | 8,783 | $3.68M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 11,469 | 9,974 | $456K |
| 80053 | Comprehensive metabolic panel | 1.9% | 33,951 | 28,404 | $323K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 12,075 | 10,008 | $312K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 32,046 | 27,259 | $271K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 4,616 | 3,996 | $238K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.3% | 3,237 | 2,926 | $226K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 2,388 | 2,218 | $194K |
| 83690 | <1% | 8,612 | 7,528 | $170K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,492 | 1,097 | $160K |
85 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,843 | $108K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,435 | $73K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,773 | $71K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 24 | $56K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,941 | $45K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 948 | $42K |
| 97597 | <1% | 891 | $42K | |
| 81003 | <1% | 8,783 | $42K | |
| 11043 | <1% | 576 | $39K | |
| 84484 | <1% | 2,446 | $36K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,269 | $36K |
| 84703 | <1% | 2,188 | $36K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 718 | $31K |
| 81001 | <1% | 4,008 | $30K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 895 | $27K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,585 | $24K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,850 | $20K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 59 | $19K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 117 | $18K |
| 85027 | <1% | 2,959 | $14K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 80 | $12K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,294 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 793 | $9K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 13 | $9K |
| 87430 | <1% | 712 | $8K | |
| 87081 | <1% | 541 | $8K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 845 | $8K |
| 82803 | <1% | 433 | $7K | |
| 99152 | <1% | 336 | $7K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 40 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 147 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 116 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 117 | $4K |
| 99153 | Mod sedat endo service >5yrs | <1% | 544 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 824 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,039 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 212 | $3K |
| 86592 | <1% | 234 | $3K | |
| 87070 | <1% | 245 | $2K | |
| 87075 | <1% | 228 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 803 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 152 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 54 | $2K |
| 86850 | <1% | 128 | $2K | |
| 87205 | <1% | 274 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 36 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 32 | $1K |
| G0378 | Hospital observation service, per hour | <1% | 28 | $1K |
| 86787 | <1% | 62 | $1K | |
| 86803 | <1% | 62 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 54 | $1K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 12 | $959.28 |
| 86901 | <1% | 129 | $956.10 | |
| 86900 | <1% | 128 | $944.42 | |
| 83605 | <1% | 79 | $889.59 | |
| 85610 | <1% | 292 | $864.48 | |
| 80061 | Lipid panel | <1% | 216 | $822.70 |
| 87186 | <1% | 56 | $777.93 | |
| 86762 | <1% | 49 | $759.04 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15 | $642.60 |
| 87340 | <1% | 30 | $552.38 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 42 | $538.88 |
| 82728 | <1% | 40 | $509.28 | |
| 84425 | <1% | 13 | $505.40 | |
| 87077 | <1% | 88 | $492.89 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 21 | $483.78 |
| 84702 | <1% | 17 | $379.30 | |
| 84439 | <1% | 17 | $362.50 | |
| 83970 | <1% | 32 | $343.66 | |
| 82746 | <1% | 13 | $338.80 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 34 | $298.62 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 81 | $272.95 |
| 80069 | <1% | 50 | $253.88 | |
| 83880 | <1% | 13 | $252.70 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 137 | $245.28 |
| 87653 | <1% | 16 | $237.46 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13 | $198.65 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 349 | $184.92 |
| 83735 | <1% | 25 | $155.89 | |
| 83550 | <1% | 13 | $123.20 | |
| 83921 | <1% | 13 | $44.80 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 12 | $22.96 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 53 | $7.70 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 19 | $0.00 |
| 97605 | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.